Colchicine - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:57:00Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:57, 20 March 2026
Line 105:		Line 105:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Add SMW Indications by Condition query table

2026-03-20T18:20:04Z

Add SMW Indications by Condition query table

← Older revision		Revision as of 18:20, 20 March 2026
Line 95:		Line 95:

	==Comments==		==Comments==

			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Colchicine]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|mainlabel=-
			\|sort=Has Indication
			\|limit=50
			}}


	==See Also==		==See Also==

ClaireLewis at 17:48, 20 September 2019

2019-09-20T17:48:54Z

← Older revision		Revision as of 17:48, 20 September 2019
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Antigout		*Type: Antigout, anti-inflammatory
	*Dosage Forms: Capsules, Tablets		*Dosage Forms: Capsules, Tablets
	*Routes of Administration: Oral		*Routes of Administration: Oral
Line 101:		Line 101:
	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Rheumatology]]

Rossdonaldson1: /* See Also */

2018-08-12T20:10:19Z

Therriac: /* Toxicity */

2018-08-10T23:03:52Z

Toxicity

← Older revision		Revision as of 23:03, 10 August 2018
Line 83:		Line 83:
	*Prevent activation, migration and degranulation of neutrophils mediating some gout symptoms.		*Prevent activation, migration and degranulation of neutrophils mediating some gout symptoms.

	==Toxicity==		==[[Colchicine toxicity\|Toxicity]]==
	*Rapidly absorbed and extensively distributed		*Rapidly absorbed and extensively distributed
	*Maximum therapeutic dose: 8-10 mg in 1 day		*Maximum therapeutic dose: 8-10 mg in 1 day

DrKarb: /* Toxicity */

2018-02-21T14:31:07Z

Toxicity

← Older revision		Revision as of 14:31, 21 February 2018
Line 87:		Line 87:
	*Maximum therapeutic dose: 8-10 mg in 1 day		*Maximum therapeutic dose: 8-10 mg in 1 day
	*Nausea, vomiting, abdominal pain, bloody diarrhea		*Nausea, vomiting, abdominal pain, bloody diarrhea
			*Bone marrow suppression, renal failure
	*Lactic Acidosis		*Lactic Acidosis
	*Delirium, seizures, coma		*Delirium, seizures, coma
	*Death within 8-36 hours caused by respiratory failure or arrhythmia		*Death within 8-36 hours caused by respiratory failure or arrhythmia
	*Aggressive supportive care (colchicine-specific antibodies are not available in U.S.)		*Aggressive supportive care (colchicine-specific antibodies are not available in U.S.)
			*If survival, can see rebound leukocytosis and transient alopecia

	==Comments==		==Comments==

Bisakson at 16:27, 4 April 2017

2017-04-04T16:27:08Z

← Older revision		Revision as of 16:27, 4 April 2017
Line 82:		Line 82:
	*Disrupts cytoskeleton function: inhibit beta-tubulin polymerization into microtubules.		*Disrupts cytoskeleton function: inhibit beta-tubulin polymerization into microtubules.
	*Prevent activation, migration and degranulation of neutrophils mediating some gout symptoms.		*Prevent activation, migration and degranulation of neutrophils mediating some gout symptoms.

			==Toxicity==
			*Rapidly absorbed and extensively distributed
			*Maximum therapeutic dose: 8-10 mg in 1 day
			*Nausea, vomiting, abdominal pain, bloody diarrhea
			*Lactic Acidosis
			*Delirium, seizures, coma
			*Death within 8-36 hours caused by respiratory failure or arrhythmia
			*Aggressive supportive care (colchicine-specific antibodies are not available in U.S.)

	==Comments==		==Comments==

Neil.m.young: Text replacement - "== " to "=="

2016-08-04T00:51:31Z

Text replacement - "== " to "=="

← Older revision		Revision as of 00:51, 4 August 2016
Line 14:		Line 14:

	==Pediatric Dosing==		==Pediatric Dosing==
	===Familial Mediterranean Fever===		===Familial Mediterranean Fever===
	*Children 4 to 6 years: 0.3 to 1.8mg daily in 1-2 divided doses		*Children 4 to 6 years: 0.3 to 1.8mg daily in 1-2 divided doses
	*Children 6 to 12 years: 0.9 to 1.8mg daily in 1-2 divided doses		*Children 6 to 12 years: 0.9 to 1.8mg daily in 1-2 divided doses

Rossdonaldson1: /* Pediatric Dosing */

2016-08-01T05:11:30Z

Pediatric Dosing

← Older revision		Revision as of 05:11, 1 August 2016
Line 14:		Line 14:

	==Pediatric Dosing==		==Pediatric Dosing==
	*Familial Mediterranean Fever ~~(FMF):~~		===Familial Mediterranean Fever===
	**Children 4 to 6 years: 0.3 to 1.8mg daily in 1-2 divided doses		*Children 4 to 6 years: 0.3 to 1.8mg daily in 1-2 divided doses
	**Children 6 to 12 years: 0.9 to 1.8mg daily in 1-2 divided doses		*Children 6 to 12 years: 0.9 to 1.8mg daily in 1-2 divided doses
	**Adolescents >12 years: Adult dosing		*Adolescents >12 years: Adult dosing
	*~~Gout prophylaxis~~/treatment: Adult dosing
			===Gout===
			*Prophylaxis/treatment: Adult dosing

	==Special Populations==		==Special Populations==

Rossdonaldson1: /* Gout */

2016-08-01T05:11:06Z

Gout

← Older revision		Revision as of 05:11, 1 August 2016
Line 9:		Line 9:
	*Flare treatment: Initial: 1.2mg and then 0.6mg in an hour (maximum 1.8mg within 1 hour). In patient receiving prophylaxis treatment wait for 12 h after flare dosing before resuming prophylaxis dose. Do not repeat treatment for at least 3 days (Canadian labelling recommendation)		*Flare treatment: Initial: 1.2mg and then 0.6mg in an hour (maximum 1.8mg within 1 hour). In patient receiving prophylaxis treatment wait for 12 h after flare dosing before resuming prophylaxis dose. Do not repeat treatment for at least 3 days (Canadian labelling recommendation)
	*Prophylaxis Treatment: 0.6mg twice daily (maximum 1.2mg/day) for 3 months (without tophi) to 6 months (≥1 tophi) after reaching target serum uric acid levels <ref>Khanna D. et al.2012 ACR Guidelines for Management of Gout Part I: Systemic Non-pharmacologic and Pharmacologic Therapeutic Approach to Hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10): 1431–1446.</ref>		*Prophylaxis Treatment: 0.6mg twice daily (maximum 1.2mg/day) for 3 months (without tophi) to 6 months (≥1 tophi) after reaching target serum uric acid levels <ref>Khanna D. et al.2012 ACR Guidelines for Management of Gout Part I: Systemic Non-pharmacologic and Pharmacologic Therapeutic Approach to Hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10): 1431–1446.</ref>
	*Familial Mediterranean Fever ~~(FMF):~~ 1.2mg to 2.4mg per day in 1-2 decided dose. Titrate (increase or decrease) 0.3mg daily increment based on efficacy and adverse effects.
			===Familial Mediterranean Fever===
			*1.2mg to 2.4mg per day in 1-2 decided dose. Titrate (increase or decrease) 0.3mg daily increment based on efficacy and adverse effects.

	==Pediatric Dosing==		==Pediatric Dosing==

← Older revision		Revision as of 20:10, 12 August 2018
Line 97:		Line 97:

	==See Also==		==See Also==
			*[[Colchicine toxicity]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]